In Vivo Contract Research Organization (CRO)

In Vivo Contract Research Organization (CRO)

Global In Vivo Contract Research Organization (CRO) Market to Reach US$7.1 Billion by 2030

The global market for In Vivo Contract Research Organization (CRO) estimated at US$4.5 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Small Molecules Modality, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the Large Molecules Modality segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.8% CAGR

The In Vivo Contract Research Organization (CRO) market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.3% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global In Vivo Contract Research Organization (CRO) Market - Key Trends and Drivers Summarized

Why Is In Vivo Contract Research Organization (CRO) Crucial for Preclinical and Clinical Research?

In vivo Contract Research Organizations (CROs) are essential for conducting preclinical and clinical research in drug development, focusing on studies conducted within living organisms. These CROs provide services such as animal testing, pharmacokinetics, toxicology, and efficacy studies that are vital to the early stages of drug development. In vivo studies help assess how a drug behaves in a biological system, providing critical data on its safety, bioavailability, and potential therapeutic effects. Outsourcing these services to specialized CROs allows pharmaceutical and biotechnology companies to reduce costs, accelerate research timelines, and access expertise in regulatory compliance and animal testing protocols, making in vivo CROs indispensable in the development pipeline.

How Are Technological Advancements Shaping the In Vivo CRO Market?

Technological advancements in imaging, genomics, and data analytics are significantly enhancing the capabilities of in vivo CROs. Non-invasive imaging techniques, such as MRI, PET, and CT scans, have improved the ability to monitor drug effects and disease progression in real-time, providing more precise and detailed insights into drug efficacy and toxicity. Furthermore, advancements in genetic engineering and CRISPR technology have expanded the use of animal models, allowing for more targeted studies on specific diseases or genetic conditions. Data analytics and AI are also revolutionizing the in vivo CRO landscape by enabling faster and more accurate analysis of preclinical data, reducing the time it takes to make critical decisions in the drug development process.

How Do Market Segments Define the Growth of the In Vivo CRO Market?

Service types include toxicology, pharmacokinetics, pharmacodynamics, and efficacy studies, with toxicology services accounting for the largest market share due to regulatory requirements for drug safety testing. Therapeutic areas served by in vivo CROs include oncology, cardiovascular diseases, infectious diseases, and neurological disorders, with oncology leading the market as cancer remains a primary focus of drug development. End-users include pharmaceutical companies, biotechnology firms, and academic institutions, with pharmaceutical companies being the dominant segment due to their high demand for outsourced preclinical services. The market is also expanding in emerging regions, where CRO services are increasingly outsourced to countries with lower operational costs.

What Factors Are Driving the Growth in the In Vivo CRO Market?

The growth in the in vivo CRO market is driven by several factors, including increasing demand for preclinical and clinical research, the rising complexity of drug development, and the growing trend of outsourcing research activities. As pharmaceutical companies face mounting pressure to bring new drugs to market faster and more cost-effectively, they are turning to specialized CROs to handle in vivo studies, reducing the burden on internal resources. The growing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, is driving demand for in vivo studies to develop new therapeutics. Additionally, advancements in personalized medicine and biologics are increasing the complexity of preclinical research, making CROs a critical component of the drug development process.

Select Competitors (Total 34 Featured) -

• American Preclinical Services, LLC.
• Charles River Laboratories
• Covance Inc.
• Evotec (US), Inc.
• ICON Plc
• inVentiv Health
• Parexel International
• Pharmaceutical Product Development, LLC (PPD)
• Quintiles
• Theorem Clinical research
• WuXi AppTec, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.